Increased Twist expression in advanced stage of mycosis fungoides and Sezary syndrome

被引:26
作者
Goswami, Meghali [1 ]
Duvic, Madeleine [1 ]
Dougherty, Alexis [1 ]
Ni, Xiao [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX 77030 USA
关键词
c-myc; mycosis fungoides; p53; Sezary syndrome; Twist; T-CELL LYMPHOMA; EPITHELIAL-MESENCHYMAL TRANSITION; GENE-EXPRESSION; UP-REGULATION; INTERNATIONAL-SOCIETY; CUTANEOUS-LYMPHOMAS; PROGNOSTIC-FACTORS; DOWN-REGULATION; CANCER; STAT3;
D O I
10.1111/j.1600-0560.2012.01883.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: The mechanisms of tumor progression in mycosis fungoides (MF) and Sezary syndrome (SS) are poorly understood. Twist, a transcription factor, is thought to promote solid tumor progression by blocking p53 and inhibiting c-myc-induced apoptosis. Whether Twist expression is correlated to MF/SS stages remains unknown. Methods: Twist, c-myc and p53 proteins in 68 MF/SS lesions across all T stages were examined by immunohistochemistry, and mRNA levels in peripheral blood CD4+ T-cells from SS patients were measured by real-time quantitative polymerase chain reaction. Results: Positive staining for Twist was found in 12.5% (2/16) of T1 and 33.3% (7/21) of T2 early stage patches/plaques compared to 50.0% (9/18) of T3 tumors and 84.6% (11/13) of T4 erythroderma. Most T4 erythroderma were positive for Twist in dermal lymphocytes, with the strongest staining. Positive staining for c-myc was higher in T3/T4 lesions (29/31, 93.5%) than T1/T2 lesions (25/37, 67.6%, p < 0.05), with strongest staining in T3 tumors. Aberrant p53 expression was more common in T3/T4 lesions (8/31, 25.8%) than in T1/T2 lesions (2/37, 5.4%, p < 0.05). Twist mRNA was detected in all CD4+ T cells from SS patients but not in normal donors. Conclusions: Increased Twist protein expression in advanced MF/SS lesions suggests that Twist expression may correlate with MF/SS stages.
引用
收藏
页码:500 / 507
页数:8
相关论文
共 43 条
[1]   Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sezary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal [J].
Agar, Nita Sally ;
Wedgeworth, Emma ;
Crichton, Siobhan ;
Mitchell, Tracey J. ;
Cox, Michael ;
Ferreira, Silvia ;
Robson, Alistair ;
Calonje, Eduardo ;
Stefanato, Catherine M. ;
Wain, Elizabeth Mary ;
Wilkins, Bridget ;
Fields, Paul A. ;
Dean, Alan ;
Webb, Katherine ;
Scarisbrick, Julia ;
Morris, Stephen ;
Whittaker, Sean J. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) :4730-4739
[2]  
BAER R, 1993, SEMIN CANCER BIOL, V4, P341
[3]   STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma [J].
Brender, C ;
Nielsen, M ;
Kaltoft, K ;
Mikkelsen, G ;
Zhang, Q ;
Wasik, M ;
Billestrup, N ;
Odum, N .
BLOOD, 2001, 97 (04) :1056-1062
[4]   Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors [J].
Campbell, James J. ;
Clark, Rachael A. ;
Watanabe, Rei ;
Kupper, Thomas S. .
BLOOD, 2010, 116 (05) :767-771
[5]   TWIST IS REQUIRED IN HEAD MESENCHYME FOR CRANIAL NEURAL-TUBE MORPHOGENESIS [J].
CHEN, ZF ;
BEHRINGER, RR .
GENES & DEVELOPMENT, 1995, 9 (06) :686-699
[6]   Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function [J].
Cheng, George Z. ;
Zhang, WeiZhou ;
Sun, Mei ;
Wang, Qi ;
Coppola, Domenico ;
Mansour, Mena ;
Xu, Limei ;
Costanzo, Carliann ;
Cheng, Jin Q. ;
Wang, Lu-Hai .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (21) :14665-14673
[7]   Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia [J].
Cosset, Erika ;
Hamdan, Ghassan ;
Jeanpierre, Sandrine ;
Voeltzel, Thibault ;
Sagorny, Karen ;
Hayette, Sandrine ;
Mahon, Francois-Xavier ;
Dumontet, Charles ;
Puisieux, Alain ;
Nicolini, Franck E. ;
Maguer-Satta, Veronique .
BLOOD, 2011, 117 (05) :1673-1676
[8]   Transformation of mycosis fungoides/Sezary syndrome: Clinical characteristics and prognosis [J].
Diamandidou, E ;
Colome-Grimmer, M ;
Fayad, L ;
Duvic, M ;
Kurzrock, R .
BLOOD, 1998, 92 (04) :1150-1159
[9]   Mycosis fungoides: Pathophysiology and emerging therapies [J].
Duvic, Madeleine ;
Foss, Francine M. .
SEMINARS IN ONCOLOGY, 2007, 34 (06) :S21-S28
[10]   Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL) [J].
Duvic, Madeleine ;
Talpur, Rakshandra ;
Ni, Xiao ;
Zhang, Chunlei ;
Hazarika, Parul ;
Kelly, Cecilia ;
Chiao, Judy H. ;
Reilly, John F. ;
Ricker, Justin L. ;
Richon, Victoria M. ;
Frankel, Stanley R. .
BLOOD, 2007, 109 (01) :31-39